复星医药：控股子公司筹划转让上海克隆100%股权

Core Viewpoint - Fosun Pharma (600196) announced on September 26 that it plans to divest 100% equity of Shanghai Clone, aiming to focus on core business and enhance asset operational efficiency [1] Group 1: Transaction Details - Fosun Pharma Industry intends to invest 54.6 million yuan as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's property share [1] - Following the establishment of the special fund, Fosun Pharma Industry plans to transfer its 100% equity in Shanghai Clone and related debts to the special fund or its controlling entity for no more than 1.256 billion yuan [1]